Bioventus, Inc. Class A BVS 深 滬
已收盤 06-12 16:00:00 美东时间
8.51
-0.170
-1.96%
華盛通- 最 高8.75
- 今 開8.75
- 成交量 46.32万股
- 最 低 8.485
- 昨 收 8.68
- 總市值 7.11亿
- 52周最高 11.2493
- 市盈率 靜 25.80
- 換手率 0.55%
- 52周最低 5.81
- 委 比 -67.55%
- 總股本 8353.48万
- 歷史最高 19.941
- 量 比 0.87
- 振 幅 3.05%
- 歷史最低 0.7999
- 每 手 1
- 風險率 1.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Bioventus holds annual shareholder meeting, elects directors
Bioventus holds annual shareholder meeting, elects directors Bioventus held its annual shareholder meeting on June 3, 2026. Shareholders backed the board’s slate of director nominees. Grant Thornton LLP was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31,
06-04 19:54
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
Bioventus Inc. announced that Mark Singleton, its Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026, at 4:00 p.m. ET. A live webcast will be available on the company’s website, www.bioventus.com, with a replay following the event. Bioventus, a global leader in innovations for active healing, focuses on delivering cost-effective, clinically prove...
06-02 11:00
Transcript: Bioventus Q1 2026 Earnings Conference Call
Bioventus (NASDAQ:BVS) released first-quarter financial results and hosted an e...
06-01 18:46
Bioventus Affirms Outlook After FDA Device Reclassification
Bioventus ( ($BVS) ) just unveiled an announcement. On April 16, 2026, the U.S....
05-22 07:14
Bioventus Says FDA Reclassifies Exogen Ultrasound Bone Healing System To Class II Device On April 16, 2026; CMS Updates Medicare Fee Schedule For Non-Invasive Bone Growth Stimulators Effective May 18, 2026; Does Not Expect Material Impact From Exogen Reimbursement Changes In FY26; Reiterates 2026 Financial Guidance - SEC Filing
On April 16, 2026, the U.S. Food and Drug Administration ("FDA") issued a final order reclassifying non-invasive bone growth stimulators, including the Company's Exogen® Ultrasound Bone Healing System, from Class
05-22 05:18
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Bioventus Raises FY2026 Adj EPS Guidance from $0.73-$0.77 to $0.75-$0.79 vs $0.75 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $604.747M Est
Bioventus (NASDAQ:BVS) raises FY2026 Adj EPS guidance from $0.73-$0.77 to $0.75-$0.79 vs $0.75 analyst estimate. Affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.000 million-$610.000 million vs
05-06 19:33
Bioventus Q1 Adj. EPS $0.15 Beats $0.10 Estimate, Sales $132.089M Beat $129.850M Estimate
Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.10 by 50 percent. This is a 87.5 percent increase over earnings of $0.08 per share from the same
05-06 19:31
Bioventus announces annual shareholder meeting
Bioventus announces annual shareholder meeting Bioventus scheduled virtual annual stockholders meeting for June 3, 2026. Meeting agenda includes election of 12 directors to serve until 2027 annual meeting. Stockholders will vote on ratification of Grant Thornton as independent registered public acco
04-22 19:52
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BNB Plus (NASDAQ:BNBX) stock moved upwards by 12.7% to $0.65 during Tu...
04-15 05:05
